Latest news and press releases about Maze Therapeutics, Inc. (MAZE): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatmen...
Price
| Price | $23.91 |
| Market Cap | $1.3B |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 3.14 |
| EV / EBITDA | -9.45 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -34.94% |
| Return on Invested Capital | -28.35% |
| Return on Assets | -25.13% |
| Gross Margin | 95.28% |
| Operating Margin | -728.06% |
| Net Margin | -667.95% |
Related companies: ARDX · BCRX · IMNM · NTLA · PHVS · SION · SYRE
Explore sector: Healthcare · Biotechnology
More sections of MAZE: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks